First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma—A Retrospective Study-Reference-Cited by-同舟云学术

First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma—A Retrospective Study

Published:2019-08-02 Issue: Volume:9 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Viscuse Paul V.,Price Katharine A.,Garcia Joaquin J.,Schembri-Wismayer David J.,Chintakuntlawar Ashish V.

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference16 articles.

1. Systemic therapy in the palliative management of advanced salivary gland cancers;Laurie;J Clin Oncol.,2006

2. Salivary duct carcinoma;D'Heygere;Curr Opin Otolaryngol Head Neck Surg.,2018

3. Characterization, treatment and outcomes of salivary ductal carcinoma using the National Cancer Database;Osborn;Oral Oncol.,2017

4. Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases;Lewis;Cancer.,1996

5. Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial;Hitre;Br J Cancer.,2013

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Apalutamide and Goserelin for Androgen Receptor–Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU;Clinical Cancer Research;2024-06-28

2. Androgen receptor activity inversely correlates with immune cell infiltration and immunotherapy response across multiple cancer lineages;2024-05-14

3. Salivary gland carcinoma: Towards a more personalised approach;Cancer Treatment Reviews;2024-03

4. HER2-targeted therapies for salivary gland cancers;Oral Oncology;2024-01

5. Efficacy of Cetuximab Combined with Paclitaxel in Patients with Recurrent Salivary Gland Carcinoma: A Retrospective Observational Study;ORL;2023-12-13